grade
pharmaceutical primary standard
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
General description
本品按现行药典规定交付。所有为支持本产品而提供的信息，包括SDS和任何产品信息单均由药典颁发机构制定并发布。 如需进一步信息和支持，请访问现行药典网站。
Application
人凝血因子VIII 浓缩物EP 参考标准品设计用于欧洲药典规定的实验室测试。
Packaging
本品按照现行药典要求提供。有关当前单位数量，请见EDQM 参考目录。
Other Notes
可能适用相应的销售限制。
Disclaimer
仅供研究使用。本品在法国的科研应用受到监管，包括用于进口和出口活动（法国《公共卫生法典》Public Health Code Article L 1211-1 paragraph 2）。如《公共卫生法典》所述，购买者（即最终用户）需要从法国研究部(France Ministry of Research)获得进口授权。订购此产品即代表您已确认获得合法的进口授权。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
Innovations in coagulation: improved options for treatment of hemophilia A and B.
Ingrid Pabinger-Fasching et al.
Thrombosis research, 131 Suppl 2, S1-S1 (2013-03-30)
Puneet Gaitonde et al.
The Journal of biological chemistry, 288(24), 17051-17056 (2013-05-08)
Administration of recombinant factor VIII (FVIII), an important co-factor in blood clotting cascade, elicits unwanted anti-FVIII antibodies in hemophilia A (HA) patients. Previously, FVIII associated with phosphatidylserine (PS) showed significant reduction in the anti-FVIII antibody response in HA mice. The
Stefan Schulte
Thrombosis research, 131 Suppl 2, S2-S6 (2013-03-30)
Albumin fusion technology has been used to enhance the pharmacokinetic properties of recombinant coagulation factors. The goal of linking albumin to coagulation factors is to extend the half-life of the coagulation factor, thereby allowing for less frequent dosing for patients
Samantha C Gouw et al.
Blood, 121(20), 4046-4055 (2013-04-05)
The objective of this study was to examine the association of the intensity of treatment, ranging from high-dose intensive factor VIII (FVIII) treatment to prophylactic treatment, with the inhibitor incidence among previously untreated patients with severe hemophilia A. This cohort
Elizabeth Duncan et al.
Methods in molecular biology (Clifton, N.J.), 992, 321-333 (2013-04-03)
Hemophilia A is an inherited bleeding disorder caused by a deficiency of factor VIII coagulant activity (FVIII:C). Patients are treated with infusions of either plasma-derived or recombinant factor VIII. However, some patients develop inhibitory antibodies (inhibitors) to infused factor VIII
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持